Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,338 |
Ending reported balance
After 2026-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 298,338 Row 2 · 2026-03-18 · Grant · Acquired 4,000 · Balance 302,338 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 26, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.49 | $261.45 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 29 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,075 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 23, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.55 | $267.75 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 28 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,970 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 22, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.51 | $263.55 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 27 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,865 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 21, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.59 | $271.95 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 26 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,760 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 20, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.54 | $266.70 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 25 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,655 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 19, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.56 | $268.80 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 24 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,550 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 16, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.49 | $286.35 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 23 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,445 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 15, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.47 | $284.05 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 22 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,330 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 14, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.51 | $288.65 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,215 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 13, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.45 | $281.75 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,100 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 12, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.46 | $282.90 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,985 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 09, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 60 | $2.21 | $132.60 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,870 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 08, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.22 | $255.30 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,810 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 07, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.24 | $257.60 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,695 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 06, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.15 | $247.25 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,580 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 02, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.42 | $278.30 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,465 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 01, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.39 | $274.85 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,350 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 31, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.36 | $271.40 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,235 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 30, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.38 | $273.70 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,120 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 29, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 115 | $2.44 | $280.60 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,005 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 26, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.55 | $280.50 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,890 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 25, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.62 | $288.20 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,780 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 24, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.59 | $284.90 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,670 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 23, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.59 | $284.90 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 6 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,560 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 22, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.51 | $276.10 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 5 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,450 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 19, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.35 | $258.50 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,340 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 18, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.23 | $245.30 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,230 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 17, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.31 | $254.10 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,120 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 16, 2022 Filed Sep 30, 2022 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.35 | $258.50 |
DisclosureSEC source: 0001209191-22-051665 · doc4.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,010 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 15, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 110 | $2.45 | $269.50 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 28 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,900 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 12, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 138 | $2.52 | $347.76 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 27 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,790 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 11, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 138 | $2.46 | $339.48 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 26 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,652 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 10, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 138 | $2.19 | $302.22 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 25 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,514 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 09, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 138 | $2.19 | $302.22 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 24 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,376 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 08, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 138 | $2.19 | $302.22 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 23 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,238 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 05, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.12 | $262.88 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 22 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,100 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 04, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.17 | $269.08 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,976 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 03, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 50 | $2.45 | $122.50 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,852 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| August 01, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.34 | $290.16 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,802 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 29, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.28 | $282.72 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,678 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 28, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.28 | $282.72 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,554 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 27, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $2.36 | $212.40 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,430 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 26, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.47 | $306.28 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,340 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 25, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.48 | $307.52 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,216 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 22, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.53 | $313.72 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,092 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 21, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.54 | $314.96 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,968 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 20, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.52 | $312.48 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,844 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 19, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.47 | $306.28 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,720 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 18, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 124 | $2.41 | $298.84 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,596 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 15, 2022 Filed Aug 19, 2022 21:28 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 144 | $2.23 | $321.12 |
DisclosureSEC source: 0001209191-22-046894 · doc4.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,472 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.